HU176557B - Process for producing acetamidoxime derivatives of benzofurane - Google Patents
Process for producing acetamidoxime derivatives of benzofurane Download PDFInfo
- Publication number
- HU176557B HU176557B HU76LA901A HULA000901A HU176557B HU 176557 B HU176557 B HU 176557B HU 76LA901 A HU76LA901 A HU 76LA901A HU LA000901 A HULA000901 A HU LA000901A HU 176557 B HU176557 B HU 176557B
- Authority
- HU
- Hungary
- Prior art keywords
- ethyl
- benzofuranyl
- formula
- oxadiazol
- acetamidoxime
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 37
- 230000008569 process Effects 0.000 title claims description 7
- AEXITZJSLGALNH-UHFFFAOYSA-N n'-hydroxyethanimidamide Chemical class CC(N)=NO AEXITZJSLGALNH-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 71
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 4
- 238000010438 heat treatment Methods 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- -1 dimethylamino, diethylamino, di-n-propylamino Chemical group 0.000 claims description 125
- 238000002360 preparation method Methods 0.000 claims description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 238000007142 ring opening reaction Methods 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 239000000460 chlorine Chemical group 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 25
- 239000000203 mixture Substances 0.000 abstract description 12
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 8
- 239000007858 starting material Substances 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 230000001882 diuretic effect Effects 0.000 abstract description 5
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 abstract 2
- 230000005792 cardiovascular activity Effects 0.000 abstract 1
- ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical class O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 123
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 62
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- 229960004592 isopropanol Drugs 0.000 description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 206010020772 Hypertension Diseases 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 238000001953 recrystallisation Methods 0.000 description 16
- 230000004872 arterial blood pressure Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 239000003208 petroleum Substances 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 11
- JYXQXKHTALMLNI-UHFFFAOYSA-N 2-(2-ethyl-1-benzofuran-3-yl)-n-hydroxy-n'-(2-morpholin-4-ylethyl)ethanimidamide Chemical compound CCC=1OC2=CC=CC=C2C=1CC(NO)=NCCN1CCOCC1 JYXQXKHTALMLNI-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002220 antihypertensive agent Substances 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 229940030600 antihypertensive agent Drugs 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- VLWINELGTMKBKV-UHFFFAOYSA-N 2-(2-ethyl-1-benzofuran-3-yl)-2-methylpropanenitrile Chemical compound C1=CC=C2C(C(C)(C)C#N)=C(CC)OC2=C1 VLWINELGTMKBKV-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- 231100000816 toxic dose Toxicity 0.000 description 3
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- SNFAMSJEKJVIDA-UHFFFAOYSA-N 2-(2-ethyl-1-benzofuran-3-yl)-n'-hydroxy-2-methylpropanimidamide Chemical compound C1=CC=C2C(C(C)(C)C(N)=NO)=C(CC)OC2=C1 SNFAMSJEKJVIDA-UHFFFAOYSA-N 0.000 description 2
- GQDGLWUFLGHKON-UHFFFAOYSA-N 2-(2-ethyl-1-benzofuran-3-yl)-n'-hydroxyethanimidamide;hydrochloride Chemical compound Cl.C1=CC=C2C(CC(N)=NO)=C(CC)OC2=C1 GQDGLWUFLGHKON-UHFFFAOYSA-N 0.000 description 2
- PVWUVYBOLVWWHC-UHFFFAOYSA-N 2-(2-ethyl-1-benzofuran-3-yl)-n'-hydroxypropanimidamide Chemical compound C1=CC=C2C(C(C)C(N)=NO)=C(CC)OC2=C1 PVWUVYBOLVWWHC-UHFFFAOYSA-N 0.000 description 2
- RWCHGCSLPRNFRX-UHFFFAOYSA-N 2-(2-ethyl-1-benzofuran-3-yl)acetonitrile Chemical compound C1=CC=C2C(CC#N)=C(CC)OC2=C1 RWCHGCSLPRNFRX-UHFFFAOYSA-N 0.000 description 2
- CZHCRQQBKVCVAQ-UHFFFAOYSA-N 2-(2-ethyl-1-benzofuran-3-yl)butanenitrile Chemical compound C1=CC=C2C(C(C#N)CC)=C(CC)OC2=C1 CZHCRQQBKVCVAQ-UHFFFAOYSA-N 0.000 description 2
- YYDJLSNJCWIFMW-UHFFFAOYSA-N 2-(2-ethyl-1-benzofuran-3-yl)propanenitrile Chemical compound C1=CC=C2C(C(C)C#N)=C(CC)OC2=C1 YYDJLSNJCWIFMW-UHFFFAOYSA-N 0.000 description 2
- JQQKLSYCABAIJP-UHFFFAOYSA-N 2-(2-ethyl-1-benzofuran-3-yl)propanoic acid Chemical compound C1=CC=C2C(C(C)C(O)=O)=C(CC)OC2=C1 JQQKLSYCABAIJP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229960004486 desoxycorticosterone acetate Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000003457 ganglion blocking agent Substances 0.000 description 2
- 230000002005 ganglioplegic effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- TVEGBGLLZMPPOI-UHFFFAOYSA-N n'-hydroxyethanimidamide;dihydrochloride Chemical compound Cl.Cl.CC(N)=NO TVEGBGLLZMPPOI-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- PEKBDPWIKMPIIL-UHFFFAOYSA-N (2-ethyl-1-benzofuran-3-yl)methyl acetate Chemical compound C1=CC=C2C(COC(C)=O)=C(CC)OC2=C1 PEKBDPWIKMPIIL-UHFFFAOYSA-N 0.000 description 1
- LKAMWXDMKZWCAQ-UHFFFAOYSA-N 1-[3-(3-pyrrolidin-1-ylpropoxy)propyl]pyrrolidine Chemical compound C1CCCN1CCCOCCCN1CCCC1 LKAMWXDMKZWCAQ-UHFFFAOYSA-N 0.000 description 1
- BSWXCJNTUHILJA-UHFFFAOYSA-N 2-(1-benzofuran-2-yl)-n'-hydroxyethanimidamide Chemical class C1=CC=C2OC(CC(N)=NO)=CC2=C1 BSWXCJNTUHILJA-UHFFFAOYSA-N 0.000 description 1
- CGOCURCQCQWCAJ-UHFFFAOYSA-N 2-(2-ethyl-1-benzofuran-3-yl)-n'-hydroxyethanimidamide Chemical compound C1=CC=C2C(CC(N)=NO)=C(CC)OC2=C1 CGOCURCQCQWCAJ-UHFFFAOYSA-N 0.000 description 1
- XFSLKSZBLORVIX-UHFFFAOYSA-N 2-(2-ethyl-1-benzofuran-3-yl)-n-hydroxy-2-methyl-n'-(2-morpholin-4-ylethyl)propanimidamide Chemical compound CCC=1OC2=CC=CC=C2C=1C(C)(C)C(NO)=NCCN1CCOCC1 XFSLKSZBLORVIX-UHFFFAOYSA-N 0.000 description 1
- XEMJGHVNVXGIBT-UHFFFAOYSA-N 2-(2-ethyl-1-benzofuran-3-yl)-n-hydroxy-n'-(2-morpholin-4-ylethyl)butanimidamide Chemical compound CCC=1OC2=CC=CC=C2C=1C(CC)C(=NO)NCCN1CCOCC1 XEMJGHVNVXGIBT-UHFFFAOYSA-N 0.000 description 1
- FCJSCJKNOCHQCU-UHFFFAOYSA-N 2-(2-ethyl-1-benzofuran-3-yl)propanoyl chloride Chemical compound C1=CC=C2C(C(C)C(Cl)=O)=C(CC)OC2=C1 FCJSCJKNOCHQCU-UHFFFAOYSA-N 0.000 description 1
- YCCKYDULBTUVPT-UHFFFAOYSA-N 2-(5-chloro-2-ethyl-1-benzofuran-3-yl)-n-hydroxy-n'-(2-morpholin-4-ylethyl)ethanimidamide Chemical compound CCC=1OC2=CC=C(Cl)C=C2C=1CC(NO)=NCCN1CCOCC1 YCCKYDULBTUVPT-UHFFFAOYSA-N 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- BIGWXAGEQONZGD-UHFFFAOYSA-N 2h-oxadiazol-5-one Chemical compound O=C1C=NNO1 BIGWXAGEQONZGD-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- LHAQSTYOHZPIBJ-UHFFFAOYSA-N C(C(=O)O)(=O)O.C(C)(NCCN1CCOCC1)=NO.C(C(=O)O)(=O)O.C(C(=O)O)(=O)O.O1CCN(CC1)CCNC(C)=NO Chemical compound C(C(=O)O)(=O)O.C(C)(NCCN1CCOCC1)=NO.C(C(=O)O)(=O)O.C(C(=O)O)(=O)O.O1CCN(CC1)CCNC(C)=NO LHAQSTYOHZPIBJ-UHFFFAOYSA-N 0.000 description 1
- YMUCMQQYZJZIKS-UHFFFAOYSA-N C1(=CC=CC=C1)C=1OC2=C(C1CC(N)=NO)C=CC=C2 Chemical compound C1(=CC=CC=C1)C=1OC2=C(C1CC(N)=NO)C=CC=C2 YMUCMQQYZJZIKS-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 206010057615 Endocrine hypertension Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000551546 Minerva Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010067598 Neurogenic hypertension Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 241000489523 Veratrum Species 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 231100001133 acute intoxication condition Toxicity 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical class C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229940119740 deoxycorticosterone Drugs 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- VPBPOXIFRZBJEU-UHFFFAOYSA-L iron(2+);dinitrite Chemical compound [Fe+2].[O-]N=O.[O-]N=O VPBPOXIFRZBJEU-UHFFFAOYSA-L 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003801 laryngeal nerve Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- DGEYTDCFMQMLTH-UHFFFAOYSA-N methanol;propan-2-ol Chemical compound OC.CC(C)O DGEYTDCFMQMLTH-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940017219 methyl propionate Drugs 0.000 description 1
- CSXSCJPKUQRGBB-UHFFFAOYSA-N n-hydroxy-2-(2-methyl-1-benzofuran-3-yl)-n'-(2-morpholin-4-ylethyl)ethanimidamide Chemical compound CC=1OC2=CC=CC=C2C=1CC(=NO)NCCN1CCOCC1 CSXSCJPKUQRGBB-UHFFFAOYSA-N 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- ZDYUUBIMAGBMPY-UHFFFAOYSA-N oxalic acid;hydrate Chemical compound O.OC(=O)C(O)=O ZDYUUBIMAGBMPY-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000003730 sympathetic denervation Effects 0.000 description 1
- 230000000194 sympathicotonic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940057613 veratrum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB52475/75A GB1508210A (en) | 1975-12-22 | 1975-12-22 | Benzofuran-derived amidoximes and process for preparing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HU176557B true HU176557B (en) | 1981-03-28 |
Family
ID=10464059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU76LA901A HU176557B (en) | 1975-12-22 | 1976-12-21 | Process for producing acetamidoxime derivatives of benzofurane |
Country Status (28)
| Country | Link |
|---|---|
| JP (1) | JPS52102268A (en:Method) |
| AR (1) | AR212605A1 (en:Method) |
| AT (1) | AT354430B (en:Method) |
| AU (1) | AU503931B2 (en:Method) |
| BE (1) | BE849430A (en:Method) |
| CA (1) | CA1080723A (en:Method) |
| CH (1) | CH617688A5 (en:Method) |
| DD (1) | DD127762A5 (en:Method) |
| DE (1) | DE2657902A1 (en:Method) |
| DK (1) | DK577276A (en:Method) |
| ES (1) | ES454421A1 (en:Method) |
| FI (1) | FI60395C (en:Method) |
| FR (1) | FR2336127A1 (en:Method) |
| GB (1) | GB1508210A (en:Method) |
| HU (1) | HU176557B (en:Method) |
| IE (1) | IE44753B1 (en:Method) |
| IT (1) | IT1123948B (en:Method) |
| MX (1) | MX3927E (en:Method) |
| NL (1) | NL7613753A (en:Method) |
| NO (1) | NO144794C (en:Method) |
| NZ (1) | NZ182809A (en:Method) |
| OA (1) | OA05521A (en:Method) |
| PL (1) | PL102695B1 (en:Method) |
| PT (1) | PT65971B (en:Method) |
| SE (1) | SE429233B (en:Method) |
| SU (1) | SU598564A3 (en:Method) |
| YU (1) | YU309376A (en:Method) |
| ZA (1) | ZA767241B (en:Method) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3398941A1 (en) * | 2017-05-03 | 2018-11-07 | AXXAM S.p.A. | Heterocyclic p2x7 antagonists |
-
1975
- 1975-12-22 GB GB52475/75A patent/GB1508210A/en not_active Expired
-
1976
- 1976-12-03 IE IE2663/76A patent/IE44753B1/en unknown
- 1976-12-06 ZA ZA767241A patent/ZA767241B/xx unknown
- 1976-12-06 NZ NZ182809A patent/NZ182809A/xx unknown
- 1976-12-10 NL NL7613753A patent/NL7613753A/xx not_active Application Discontinuation
- 1976-12-13 AR AR265814A patent/AR212605A1/es active
- 1976-12-14 AU AU20534/76A patent/AU503931B2/en not_active Expired
- 1976-12-14 FR FR7637622A patent/FR2336127A1/fr active Granted
- 1976-12-15 BE BE173280A patent/BE849430A/xx not_active IP Right Cessation
- 1976-12-15 MX MX765235U patent/MX3927E/es unknown
- 1976-12-15 CA CA267,918A patent/CA1080723A/en not_active Expired
- 1976-12-15 FI FI763604A patent/FI60395C/fi not_active IP Right Cessation
- 1976-12-15 PT PT65971A patent/PT65971B/pt unknown
- 1976-12-20 CH CH1603476A patent/CH617688A5/fr not_active IP Right Cessation
- 1976-12-20 ES ES454421A patent/ES454421A1/es not_active Expired
- 1976-12-20 YU YU03093/76A patent/YU309376A/xx unknown
- 1976-12-21 DK DK577276A patent/DK577276A/da not_active Application Discontinuation
- 1976-12-21 AT AT948476A patent/AT354430B/de not_active IP Right Cessation
- 1976-12-21 HU HU76LA901A patent/HU176557B/hu unknown
- 1976-12-21 SU SU762430683A patent/SU598564A3/ru active
- 1976-12-21 PL PL1976194589A patent/PL102695B1/pl unknown
- 1976-12-21 NO NO76764332A patent/NO144794C/no unknown
- 1976-12-21 DE DE19762657902 patent/DE2657902A1/de not_active Withdrawn
- 1976-12-21 IT IT7630679A patent/IT1123948B/it active
- 1976-12-21 SE SE7614368A patent/SE429233B/xx unknown
- 1976-12-22 JP JP15558976A patent/JPS52102268A/ja active Pending
- 1976-12-22 DD DD7600196548A patent/DD127762A5/xx unknown
- 1976-12-22 OA OA56023A patent/OA05521A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH672127A5 (en:Method) | ||
| KR20020033778A (ko) | 설포닐 카복스아미드 유도체, 이의 제조방법 및약제로서의 이의 용도 | |
| DE10237722A1 (de) | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase | |
| FR2613720A1 (fr) | Derives d'aryl-heteroaryl carbinols avec activite analgesique | |
| US4539322A (en) | Dihydropyridine derivatives and their use in treating heart conditions and hypertension | |
| US5391552A (en) | Diphenylpiperazine derivative and drug for circulatory organ containing the same | |
| EP0047536A2 (en) | Substituted propylamines | |
| BRPI0616217A2 (pt) | tiazolinonas e oxazolinonas e seus usos como inibidores da ptp1b | |
| PT98918B (pt) | Processo para a preparcao de aril-fundidas- e hetaril-fundidas-2,4-diazepinas e-2,4-diazocinas como agentes anti-arritmicos | |
| US4341893A (en) | Quinazoline derivatives | |
| JPH0723365B2 (ja) | フエノキシアルキルまたはチオフエノキシアルキル側鎖を有する新規ピペラジンカルボキシアミド化合物 | |
| JPS63310872A (ja) | ドーパミン−β−ヒドロキシラーゼ抑制剤 | |
| US4124710A (en) | Acetamidoxime derivatives and use thereof | |
| US4616017A (en) | Aminohydroxypropoxy substituted aryl compounds | |
| SK2722002A3 (en) | Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia | |
| HU176557B (en) | Process for producing acetamidoxime derivatives of benzofurane | |
| FR2618436A1 (fr) | Derives de piperidine, leur preparation et leur application en therapeutique | |
| US3917600A (en) | 2-(Benzofuran)-acetamidines | |
| DE3423429A1 (de) | Substituierte phenoxyalkylaminopropanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen | |
| US4029790A (en) | 1-Benzoyl-2 or 4 [2-(4-phenyl-piperazino)-ethyl]-piperidines | |
| CA1055044A (en) | Phenylalkyl esters of amino-acids having antidepressive activity | |
| US3928341A (en) | N-Aminoalkyl-4-anilino pyridines | |
| EP0187639B1 (en) | Novel piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient | |
| US4259257A (en) | 1-Phenyl-2-amino-1,3-propanediol-N-aryloxyalkyl derivatives | |
| JPH06135943A (ja) | 新規なウラシル誘導体及びそれを有効成分とするアレルギー疾患治療薬 |